A 28-year-old agricultural worker is admitted with organophosphate pesticide poisoning. After initial stabilization with atropine and pralidoxime, the attending physician wants to assess the severity of poisoning and monitor response to treatment. Which investigation should be repeated serially to track clinical improvement?

Explanation

## Serial Monitoring in Organophosphate Poisoning ### Investigation for Serial Monitoring **Key Point:** Red blood cell acetylcholinesterase (RBC-AChE) activity is the gold standard investigation for assessing severity and monitoring response to treatment in organophosphate poisoning. It directly reflects inhibition of the target enzyme (true acetylcholinesterase) at the neuromuscular junction and in the CNS [Harrison's Principles of Internal Medicine, 21e; KD Tripathi 8e Ch 34]. ### Why RBC-AChE for Serial Monitoring 1. **True AChE measurement**: RBC-AChE is the same enzyme (acetylcholinesterase) that is inhibited at cholinergic synapses — it is the most specific biomarker of organophosphate toxicity 2. **Severity correlation**: Activity levels correlate directly with clinical severity — mild poisoning: 20–50% of normal; moderate: 10–20%; severe: <10% 3. **Response to pralidoxime**: Serial RBC-AChE activity tracks reactivation of the enzyme by pralidoxime (oxime therapy), making it the ideal monitor of antidotal efficacy 4. **Guides treatment decisions**: Rising RBC-AChE activity confirms clinical improvement and guides weaning of atropine and supportive care 5. **Prognostic value**: Persistent low RBC-AChE despite oxime therapy suggests "aging" of the enzyme-OP complex, indicating irreversible inhibition ### Comparison: RBC-AChE vs. Serum Pseudocholinesterase | Feature | RBC-AChE | Serum Pseudocholinesterase | |---|---|---| | **Enzyme type** | True AChE (target enzyme) | Butyrylcholinesterase (non-target) | | **Specificity for OP toxicity** | High — directly reflects synaptic inhibition | Lower — also reduced in liver disease, malnutrition, pregnancy | | **Severity correlation** | Direct and reliable | Less reliable due to high inter-individual baseline variability | | **Monitoring antidote response** | Ideal — tracks pralidoxime reactivation | Less useful for tracking oxime efficacy | | **Baseline variability** | Lower inter-individual variation | High inter-individual variation (limits serial utility) | | **Clinical use** | Severity assessment + serial monitoring | Screening, initial diagnosis | ### Why Serum Pseudocholinesterase is NOT the Best Choice for Serial Monitoring - High inter-individual baseline variability makes trend interpretation unreliable without a known pre-exposure baseline - It is not the target enzyme — its recovery does not directly reflect synaptic AChE reactivation - Can be reduced by non-OP causes (hepatic disease, genetic variants), confounding interpretation ### Other Options - **Serum CK (A)**: Elevated in intermediate syndrome but not useful for serial monitoring of OP poisoning severity - **Urine OP metabolites (D)**: Confirm exposure but do not reflect ongoing enzyme inhibition or treatment response **High-Yield:** RBC-AChE activity is the most specific and reliable biomarker for both diagnosing severity and serially monitoring response to antidotal therapy (atropine + pralidoxime) in organophosphate poisoning. Serial measurements every 6–12 hours guide clinical decision-making. **Clinical Pearl:** A rising RBC-AChE activity in response to pralidoxime therapy confirms successful enzyme reactivation. If RBC-AChE fails to rise despite adequate oxime dosing, "aging" of the OP-AChE complex should be suspected, and further oxime therapy may be futile.